echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The world's first freeze-dried mRNA vaccine preclinical data release How is the progress of mRNA vaccine at home and abroad?

    The world's first freeze-dried mRNA vaccine preclinical data release How is the progress of mRNA vaccine at home and abroad?

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    A few days ago, the preclinical research data of the lyophilized mRNA COVID-19 vaccine of Ruikeji Bio, a subsidiary of Ruike Bio, was published in the biological preprint journal BioRxiv

    It is reported that the freeze-dried mRNA-LNP new coronary pneumonia vaccine adopts the LNP delivery system, and the self-developed freeze-drying technology is used to achieve formulation stability at 4°C and 25°C

    Previous studies have shown that the process of dehydration and lyophilization causes mechanical stress that can easily disrupt the structure of mRNA

    Likewise, the lyophilization process does not affect the biological activity and immunogenicity of the mRNA vaccine

    mRNA vaccines belong to nucleic acid vaccines, which are designed to deliver mRNA of virus-related sequences synthesized in vitro into human cells to form immunity

    Global marketed mRNA vaccines: Comirnaty and Spikevax

    Global marketed mRNA vaccines: Comirnaty and Spikevax

    At present, two mRNA vaccines have been launched in the world: Pfizer/BioNtech's Comirnaty and Moderna's Spikevax

    Although the mRNA vaccine has extremely strict storage and transportation temperature conditions, this has not stopped the vaccine from flourishing during the epidemic

    According to the 221-year financial report released by Pfizer earlier, the total revenue of the new crown vaccine Comirnaty reached 36.

    This shows how far-sighted Pfizer was in firmly choosing the mRNA vaccine technology route in the early days of the outbreak

    mRNA strategic roadmap

    Four latest agreements to advance mRNA strategy

    Looking at Moderna, the company's official website shows that its 2021 performance report will be released on the 24th of this month

    Domestic mRNA new crown vaccine: Fosun lincese-in, Watson lead self-developed

    Domestic mRNA new crown vaccine: Fosun lincese-in, Watson lead self-developed

    The domestic choice for the mRNA technology route is firstly the cooperation between Fosun Pharma and BioNTech

    In March 2020, Fosun Pharma took the lead and won the exclusive rights to R&D and commercialization of BioNTech in Greater China

    In 2021, while Pfizer/BioNTech's mRNA new crown vaccine is making a big splash in the global war against the epidemic, Fubitai® has successively obtained approvals in Hong Kong and Macau, China, and emergency use authorization in Taiwan, China

    In July 2021, Fosun Pharma stated that the NMPA's approval of Fubitai® has been basically completed, and it is expected to become the first mRNA new crown vaccine in China

    In August 2021, the first transcript of Forbitx Greater China was released

    In terms of independent research and development of domestic mRNA new crown vaccines, the ARCoV vaccine of Watson/Aibo, which was the first to enter the international phase III clinical trials, is undoubtedly in the "first echelon" of China's mRNA new crown vaccines

    It is reported that Aibo's mRNA vaccine can be stored below 2℃~8℃ for at least 6 months.
    Although it is not as good as the storage and transportation conditions of freeze-dried mRNA vaccine, it still greatly reduces the challenges brought by cold chain transportation

    Watson Bio has already deployed an mRNA vaccine production line in Yuxi, Yunnan Province as early as December 2020, with a total investment of 280 million yuan and an estimated production capacity of 200 million doses per year
    Against the background of the global shortage of new crown vaccine supply, if the vaccine can be successfully launched, it may bring billions of profits to Watson Bio

    Reference sources: Medical Notes, MedTrend Medical Trends, Sina Pharmaceutical News, Xinkangjie

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.